The antibiotic industry is broken

But unlike new drugs for cancer or rare diseases, prices of antibiotics are kept low in many countries, creating little incentive for drug companies to develop new ones. But the most promising idea is for drugs firms to change how they charge governments and health insurers for antibiotics, by switching to a Netflix-style subscription model. Using this model for antibiotics can square the circle of incentivising drugs companies to develop a treatment that doctors will then try to use as little as possible.

Source: www.economist.com